ArticleJournal of translational medicine2016
Bridging the gap to therapeutic strategies based on connexin/pannexin biology.
Article in Journal of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Connexin 43 C-terminus directly inhibits the hyperphosphorylation of Akt/ERK through protein-protein interactions in glioblastoma.Cancer science · 2018Pooled it
- Deceiving the gatekeepers: virus modulation of gap junctions.Microbiology and molecular biology reviews : MMBR · 2025Review
- Assessment of Gene Expression on the Gap Junction Connexin of Cumulus Cells on Infertile Women With Polycystic Ovary Syndrome and Poor Ovarian Response: The Novel Role of Propranolol.Journal of family & reproductive health · 2025Article
- Simvastatin Enhances the Cytotoxic Effects of Doxorubicin in a Mammary Adenocarcinoma Cell Model by Involving Connexin 43.Journal of biochemical and molecular toxicology · 2025Article
- The Role of the Gap Junction Protein Connexin in Adrenal Gland Tumorigenesis.International journal of molecular sciences · 2024Review
- Pannexins in the musculoskeletal system: new targets for development and disease progression.Bone research · 2024Review
- Understanding the Role of Connexins in Hepatocellular Carcinoma: Molecular and Prognostic Implications.Cancers · 2024Review
- Article
- Connexin43 in Post-Surgical Peritoneal Adhesion Formation.Life (Basel, Switzerland) · 2022Article
- New Insights into Pulmonary Hypertension: A Role for Connexin-Mediated Signalling.International journal of molecular sciences · 2021Review
- Connexin therapeutics: blocking connexin hemichannel pores is distinct from blocking pannexin channels or gap junctions.Neural regeneration research · 2021Review
- Alteration of Cx37, Cx40, Cx43, Cx45, Panx1, and Renin Expression Patterns in Postnatal Kidneys of Dab1-/- (International journal of molecular sciences · 2021Article
- Connexins-Therapeutic Targets in Cancers.International journal of molecular sciences · 2020Review
- Astrocytic Connexin43 Channels as Candidate Targets in Epilepsy Treatment.Biomolecules · 2020Review
- Signatures of the Consolidated Response of Astrocytes to Ischemic Factors In Vitro.International journal of molecular sciences · 2020Article
- Xentry-Gap19 inhibits Connexin43 hemichannel opening especially during hypoxic injury.Drug delivery and translational research · 2020Article
- Danegaptide Enhances Astrocyte Gap Junctional Coupling and Reduces Ischemic Reperfusion Brain Injury in Mice.Biomolecules · 2020Article
- Connexins in cancer: bridging the gap to the clinic.Oncogene · 2019Review
- Persistent Corneal Epithelial Defects: A Review Article.Medical hypothesis, discovery & innovation ophthalmology journal · 2019Review
- Connexin 43-Based Therapeutics for Dermal Wound Healing.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A unique workshop was recently held focusing on enhancing collaborations leading to identify and update the development of therapeutic strategies targeting connexin/pannexin large pore channels. Basic scientists exploring the functions of these channels in various pathologies gathered together with leading pharma companies which are targeting gap junction proteins for specific therapeutic applications. This highlights how paths of discovery research can converge with therapeutic strategies in innovative ways to enhance target identification and validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.